Center for Coordination of Clinical Research Network (CCRN), Institute for Clinical Research (ICR), Blok B4, National Institutes of Health (NIH), Ministry of Health (MOH), Shah Alam, Malaysia
Auto-generated profile, based on publicly available information
Nurakmal Baharum
Center for Coordination of Clinical Research Network (CCRN), Institute for Clinical Research (ICR), Blok B4, National Institutes of Health (NIH), Ministry of Health (MOH), Shah Alam, Malaysia
Excessive deposit of epicardial adipose tissue (EAT) were recently shown to be positively correlated with cardiovascular disease (CVD). This study aims to investigate the thickness of EAT and its association with the components of metabolic syndrome among multi-ethnic Malaysians with and without acute coronary syndrome (ACS). A total of 213 patients were recruited, with the thickness of EAT were quantified non-invasively using standard two-dimensional echocardiography. EAT thickness among the Malaysian population was prompted by several demographic factors and medical comorbidities, particularly T2DM and dyslipidaemia. ACS patients have significantly thicker EAT compared to those without ACS (4.1 mm vs 3.7 mm, p = 0.035). Interestingly, among all the races, Chinese had the thickest EAT distribution (4.6 mm vs 3.8 mm), with age (p = 0.04 vs p < 0.001), and overall diastolic blood pressure (p = 0.028) was also found to be associated with EAT thickness. Further study is warranted to investigate its role as a cardiovascular risk marker among Malaysians with ACS.
Epicardial adipose tissue (EAT) is an emerging cardiometabolic risk factor in type 2 diabetes mellitus (T2DM). While SGLT-2 inhibitors (SGLT-2i) offer cardiovascular benefits, their specific effects on EAT and left ventricular (LV) remodeling and function in Asian populations remain understudied. This study investigated the relationship between SGLT-2i on cardiometabolic parameters, EAT thickness and LV function in Malaysian patients with T2DM and coronary artery disease (CAD). A total of 360 patients with T2DM and CAD were divided into non-SGLT-2i and SGLT-2i groups. Anthropometric, cardiometabolic, and echocardiographic measurements were analyzed at baseline and post-6 months for 302 patients who competed the study (n = 151 per group). Both groups showed improvements in glycemic control (fasting blood glucose − 1.7 vs. − 2.6 mmol/L; HbA1c − 0.3% vs. − 0.6%; all p < 0.001). Broader cardiometabolic benefits were observed predominantly among SGLT-2i group, including greater reductions in body mass index (– 0.7 vs. − 0.3 kg/m2) and serum lipid concentrations (all p < 0.001), a marked decrease in EAT thickness (–1 .5 mm vs. + 0.6 mm, p < 0.001), and concomitant improvements in left ventricular structure, with reductions in LV mass (– 20 vs. + 7.8 g) and increased LV ejection fraction (+ 4.6% vs. − 1.0%) (all p ≤ 0.01). Within the SGLT-2i group, EAT reduction was associated with lower body weight and BMI (p < 0.05) but was independent of glycemic changes. Reductions in body weight and BMI were associated with improvements in LV diameter and mass (p < 0.05) and although not directly mediated by changes in EAT. Beyond glycemic control, SGLT-2i was associated with reduced EAT thickness and improved LV remodeling and function in Malaysian T2DM patients with CAD. The reduction in EAT thickness specifically was associated with lower body weight and BMI. These findings provide Asian population–specific evidence with distinct cardiometabolic and adiposity traits.